Literature DB >> 21255635

Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist produces anxiolytic-like effects and reverses abnormal firing activity of projection neurons in the basolateral nucleus of the amygdala in rats with bilateral 6-OHDA lesions.

Li Chen1, Jian Liu, Umar Ali, Zhen Hua Gui, Chen Hou, Ling Ling Fan, Yong Wang, Tao Wang.   

Abstract

Although 2-methyl-6-(phenylethynyl)-pyridine (MPEP), a selective metabotropic glutamate receptor 5 antagonist, improves the motor symptoms of Parkinson's disease (PD), the effects of MPEP on the psychiatric symptom of PD and the mechanism involved are still unclear. In the present study, we examined the effects of MPEP in anxiolytic-like behavior and firing activity of projection neurons in the basolateral nucleus of the amygdala (BLA) in rats with 6-hydroxydopamine (6-OHDA) injected bilaterally into dorsal striatum. Rats were divided into three groups, sham-operated group, 6-OHDA lesion with vehicle treatment group and 6-OHDA lesion with MPEP treatment group. Injection of 6-OHDA (10.5 μg) into the dorsal striatum produced 31.5% loss of tyrosine hydroxylase immunoreactive (TH-ir) neurons in the SNpc. The 6-OHDA-lesioned rats showed anxiety behavior and the firing rate of BLA projection neurons decreased significantly compared with sham-operated rats, and no difference was found in the firing pattern of these neurons. Whereas chronic, systemic treatment of MPEP (3 mg/kg/day, i.p.; 14 days) attenuated loss of TH-ir neurons, produced anxiolytic-like effect and normalized the abnormal firing rate of projection neurons of the BLA in rats with the bilateral lesions. Systemic administration of cumulative apomorphine (10-160 μg/kg, i.v.) inhibited the firing rate of BLA projection neurons in sham-operated, 6-OHDA lesion with vehicle-treated and MPEP-treated rats, but the 6-OHDA lesion decreased the response of BLA projection neurons to apomorphine stimulation, while MPEP reversed the reactivity of these neurons. These data demonstrate that the partial lesion of the nigrostriatal pathway causes anxiety symptom and decreases firing rate of BLA projection neurons in the rat. Furthermore, chronic, systemic MPEP treatment has the neuroprotective and anxiolytic-like effects, and reverses the abnormal firing rate of BLA projection neurons, suggesting that MPEP has important implication for the treatment of PD.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21255635     DOI: 10.1016/j.brainresbull.2011.01.005

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  11 in total

Review 1.  The Role of NMDA Receptors in the Development of Brain Resistance through Pre- and Postconditioning.

Authors:  Leandra Celso Constantino; Carla Inês Tasca; Carina Rodrigues Boeck
Journal:  Aging Dis       Date:  2014-02-12       Impact factor: 6.745

2.  Interaction between the mGlu receptors 5 antagonist, MPEP, and amphetamine on memory and motor functions in mice.

Authors:  Francesca Managò; Sebastien Lopez; Alberto Oliverio; Marianne Amalric; Andrea Mele; Elvira De Leonibus
Journal:  Psychopharmacology (Berl)       Date:  2012-11-29       Impact factor: 4.530

3.  The effect of URB597, exercise or their combination on the performance of 6-OHDA mouse model of Parkinson disease in the elevated plus maze, tail suspension test and step-down task.

Authors:  Mohaddeseh Ebrahimi-Ghiri; Faezeh Shahini; Mohammad-Reza Zarrindast
Journal:  Metab Brain Dis       Date:  2021-10-02       Impact factor: 3.584

Review 4.  Therapeutic potential of targeting glutamate receptors in Parkinson's disease.

Authors:  Clare Finlay; Susan Duty
Journal:  J Neural Transm (Vienna)       Date:  2014-02-21       Impact factor: 3.575

Review 5.  Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.

Authors:  Susan Duty
Journal:  CNS Drugs       Date:  2012-12       Impact factor: 5.749

6.  Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [11C]ABP688 and PET imaging study in depression.

Authors:  I Esterlis; N DellaGioia; R H Pietrzak; D Matuskey; N Nabulsi; C G Abdallah; J Yang; C Pittenger; G Sanacora; J H Krystal; R V Parsey; R E Carson; C DeLorenzo
Journal:  Mol Psychiatry       Date:  2017-04-11       Impact factor: 15.992

7.  Long-Term Depression of Striatal DA Release Induced by mGluRs via Sustained Hyperactivity of Local Cholinergic Interneurons.

Authors:  Nicola B Mercuri; Mauro Federici; Francesca Romana Rizzo; Lorenzo Maugeri; Sebastian L D'Addario; Rossella Ventura; Nicola Berretta
Journal:  Front Cell Neurosci       Date:  2021-12-02       Impact factor: 5.505

Review 8.  Group I mGluRs in Therapy and Diagnosis of Parkinson's Disease: Focus on mGluR5 Subtype.

Authors:  Shofiul Azam; Md Jakaria; JoonSoo Kim; Jaeyong Ahn; In-Su Kim; Dong-Kug Choi
Journal:  Biomedicines       Date:  2022-04-07

9.  A mouse model of non-motor symptoms in Parkinson's disease: focus on pharmacological interventions targeting affective dysfunctions.

Authors:  Alessandra Bonito-Oliva; Débora Masini; Gilberto Fisone
Journal:  Front Behav Neurosci       Date:  2014-08-27       Impact factor: 3.558

Review 10.  Neuropsychiatric Disorders in Parkinson's Disease: What Do We Know About the Role of Dopaminergic and Non-dopaminergic Systems?

Authors:  Kathy Dujardin; Véronique Sgambato
Journal:  Front Neurosci       Date:  2020-01-29       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.